Drug Trial Radar · NCT06840483
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Mar 3, 2025
Primary completion
Jun 30, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- BicycleTx LimitedIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with NECTIN4-amplified recurrent, unresectable, or metastatic breast cancer who have received prior therapy (see inclusion criteria below). The study will comprise of 2 cohorts. Cohort A will include participants with hormone receptor positive/ human epidermal growth factor receptor 2 negative \[HR+/HER2-\] breast cancer, whereas Cohort B will include participants with triple-negative breast cancer (TNBC).
Conditions
- Breast Cancer
Interventions
Zelenectide pevedotin (BT8009)Drug
Participants will receive zelenectide pevedotin on Days 1, and 8 of every 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors per RECIST version 1.1 as assessed by the InvestigatorTime frame: Up to approximately 3 years
Locations
18 sites in 7 countries. Site status is shown where the registry gives one.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC)
Baltimore, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
Siteman Cancer Center
St Louis, Missouri
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York
Duke Cancer Institute
Durham, North Carolina
Compass Oncology - Rose Quarter Cancer Center
Portland, Oregon
Texas Oncology San Antonio
San Antonio, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
UZ Leuven
Leuven, Belgium
Oncopole Claudius Regaud
Toulouse, France
Clinica Oncologica-Azienda Ospedaliero Universitaria delle Marche
Ancona, Italy
Istituto Europeo di Oncologia
Milan, Italy
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRCCS IRST
Meldola, Forli/Cesena, Italy
Hospital Quironsalud Barcelona
Barcelona, Spain
Hospital Beata Maria Ana
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
The Royal Marsden NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.